Abstract
Bacterial endotoxin [e.g. lipopolysaccharide (LPS)] can trigger systemic hyper-inflammatory that subsequently leads to multiple organ failure and lethality (gram-negative sepsis). This paper describes the development of endotoxin-neutralizing peptides that potentially treat sepsis. These peptides have been derived from bactericidal/permeability-increasing protein (BPIP), anti-microbial peptides, and leukocyte CD18 antigen and some of these peptides have been tested in clinical studies.
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antimicrobial Cationic Peptides / chemistry
-
Antimicrobial Cationic Peptides / metabolism
-
Antimicrobial Cationic Peptides / pharmacology
-
Antimicrobial Cationic Peptides / therapeutic use
-
CD18 Antigens / chemistry
-
CD18 Antigens / metabolism
-
CD18 Antigens / pharmacology
-
CD18 Antigens / therapeutic use
-
Endotoxins / antagonists & inhibitors*
-
Endotoxins / metabolism
-
Gram-Negative Bacteria / drug effects
-
Gram-Negative Bacteria / physiology*
-
Humans
-
Molecular Sequence Data
-
Peptides / chemistry
-
Peptides / metabolism
-
Peptides / pharmacology*
-
Peptides / therapeutic use*
-
Sepsis / drug therapy*
Substances
-
Antimicrobial Cationic Peptides
-
CD18 Antigens
-
Endotoxins
-
Peptides